Esmirtazapine
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Sleep Initiation and Maintenance Disorder; Elderly
Conditions
Sleep Initiation and Maintenance Disorder; Elderly, Mental Disorder, Dyssomnias, Sleep Disorders, Sleep Disorder, Intrinsic
Trial Timeline
Jan 9, 2008 → Feb 14, 2010
NCT ID
NCT00561574About Esmirtazapine
Esmirtazapine is a phase 3 stage product being developed by Merck for Sleep Initiation and Maintenance Disorder; Elderly. The current trial status is completed. This product is registered under clinical trial identifier NCT00561574. Target conditions include Sleep Initiation and Maintenance Disorder; Elderly, Mental Disorder, Dyssomnias.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00750919 | Phase 3 | Terminated |
| NCT00561574 | Phase 3 | Completed |
Competing Products
20 competing products in Sleep Initiation and Maintenance Disorder; Elderly